Date Of Birth: 29/07/1993; gender: female.
Pre-treatment Documents: 19 years 2 months old: 29/07/1993.
Diagnosis: Skeletal class II with mandibular laterognathia and retrusion, hypodivergent facial pattern; class II division 1, transverse maxillary deficiency with left unilateral posterior cross bite; missing teeth before treatment: 18 28 38 48.
Treatment Planning: Orthosurgical treatment (bimaxillary surgery); Bimaxillary lingual fixed appliances.
Duration Of Active Treatment: 2 years.
Post-treatment Documents: 22 years 5 months old; 09/01/2015.
Post-retention Documents: 05/01/2016; 23 years 5 months old.
Retention Period: 3 years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ortho.2020.05.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma.
Clin Cancer Res
January 2025
United States Food and Drug Administration, Silver Spring, Maryland, United States.
On April 23, 2024, FDA granted accelerated approval to tovorafenib, a type II RAF kinase inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Efficacy was evaluated in FIREFLY-1 (NCT04775485), a single-arm, open-label, multicenter trial that enrolled patients 6 months to 25 years of age with relapsed or refractory pLGG with an activating BRAF alteration who had received prior systemic therapy. The major efficacy outcome measure was radiologic overall response rate (ORR), defined as the proportion of patients with complete response, partial response, or minor response as determined by blinded independent central review using Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria.
View Article and Find Full Text PDFElectronic Patient-Reported Outcome System Implementation in Outpatient Cardiovascular Care: A Randomized Clinical Trial.
JAMA Netw Open
January 2025
Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
Importance: The integration of patient-reported outcome (PRO) assessments in cardiovascular care has encountered considerable obstacles despite their established clinical relevance.
Objective: To assess the impact of a physician- and patient-friendly electronic PRO (ePRO) monitoring system on the quality of cardiovascular care in clinical practice.
Design, Setting, And Participants: This open-label, multicenter, pilot randomized clinical trial was phase 2 of a multiphase study that was conducted from October 2022 to October 2023 and focused on the implementation and evaluation of an ePRO monitoring system in outpatient clinics in Japan.
Digital Meditation to Target Employee Stress: A Randomized Clinical Trial.
JAMA Netw Open
January 2025
Department of Psychiatry and Behavioral Sciences, University of California San Francisco.
Importance: Mindfulness meditation may improve well-being among employees; however, effects of digital meditation programs are poorly understood.
Objective: To evaluate the effects of digital meditation vs a waiting list condition on general and work-specific stress and whether greater engagement in the intervention moderates these effects.
Design, Setting, And Participants: This randomized clinical trial included a volunteer sample of adults (aged ≥18 years) employed at a large academic medical center who reported mild to moderate stress, had regular access to a web-connected device, and were fluent in English.
Obesity and metabolic syndrome in a diverse pediatric kidney transplant population: which anthropometric measure best predicts arterial stiffness?
Pediatr Nephrol
January 2025
Nephrology, Children's National Hospital, 111 Michigan Avenue NW, Washington, DC, 20010, USA.
Background: Obesity and metabolic syndrome (MS) accelerate arterial stiffening, increasing cardiovascular (CV) risk after transplant. BMI is limited by inability to differentiate muscle, fat mass, and fat distribution patterns. The aim of this study was to identify the best anthropometric measure to detect arterial stiffness as assessed by pulse wave velocity (PWV) in a racially diverse pediatric transplant population.
View Article and Find Full Text PDF[Do basic welfare payments in Germany cover the food costs of a healthy diet for children and adolescents?].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
January 2025
Forschungsdepartment Kinderernährung (FKE), Universitätsklinik für Kinder- und Jugendmedizin, St. Josef-Hospital, Ruhr-Universität Bochum, Bochum, Deutschland.
Introduction: Families in Germany who live in poverty receive citizens' benefits (Bürgergeld) within the context of welfare legislation. Basic rates for children and adolescents are included in these benefits and staggered into three groups according to age. The need for nutrition is the largest category of the basic rate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!